125 related articles for article (PubMed ID: 21632217)
1. Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
Hawser SP
Int J Antimicrob Agents; 2011 Aug; 38(2):186-7. PubMed ID: 21632217
[No Abstract] [Full Text] [Related]
2. IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Dixon N; Fowler RC; Yoshizumi A; Horiyama T; Ishii Y; Harrison L; Geyer CN; Moland ES; Thomson K; Hanson ND
Antimicrob Agents Chemother; 2016 Oct; 60(10):6418-21. PubMed ID: 27503648
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
5. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
6. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
7. Activity of ertapenem and comparators against recent clinical isolates from intra-abdominal abscesses (SMART 2009).
Hawser SP
J Infect; 2011 Jun; 62(6):496-7. PubMed ID: 21458487
[No Abstract] [Full Text] [Related]
8. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
11. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
14. [New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
Barboza E; Solomkin J; Goldstein EJ; del Castillo M; Alvarado R; Barboza A; Teppler H
Rev Gastroenterol Peru; 2003; 23(3):192-8. PubMed ID: 14532920
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Fujimura S; Takane H; Nakano Y; Watanabe A
J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
[No Abstract] [Full Text] [Related]
16. Killing of Escherichia coli by beta-lactams at different inocula.
Tam VH; Ledesma KR; Chang KT; Wang TY; Quinn JP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
[TBL] [Abstract][Full Text] [Related]
17. Plasmid-mediated cephalosporinase ACC-1 in clinical isolates of Proteus mirabilis and Escherichia coli.
Girlich D; Karim A; Spicq C; Nordmann P
Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):893-5. PubMed ID: 11152321
[No Abstract] [Full Text] [Related]
18. Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Teppler H; Meibohm AR; Woods GL
J Chemother; 2004 Feb; 16(1):62-9. PubMed ID: 15078001
[TBL] [Abstract][Full Text] [Related]
19. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
20. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
